trending Market Intelligence /marketintelligence/en/news-insights/trending/e4Ao-QtvdM2Am4FvvXC69A2 content esgSubNav
In This List

Pfizer-Astellas' Xtandi gets US FDA supplemental approval for prostate cancer

Blog

Insight Weekly: Banks brace for recession; Europe PE deal values soar; US solar imports rebound

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook


Pfizer-Astellas' Xtandi gets US FDA supplemental approval for prostate cancer

Pfizer Inc. and Astellas Pharma Inc. said the U.S. Food and Drug Administration approved Xtandi to treat a type of prostate cancer.

The regulator approved the companies' supplemental new drug application for Xtandi to treat metastatic castration-sensitive prostate cancer, a type of the disease in which the cancer has spread beyond the prostate and still responds to therapy to lower testosterone levels.

The drug, also known as enzalutamide, was previously approved to treat two other advanced types of the disease: Non-metastatic and metastatic castration-resistant prostate cancer.

The new approval is based on results from a phase 3 study called Arches, in which patients who received both the drug and hormone therapy lived longer without the disease worsening than those who received only the therapy.

New York's Pfizer jointly markets Xtandi in the U.S. with Tokyo-based Astellas, which commercializes the drug elsewhere.